Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 88 entries
View as:

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Phase: N/A Priority: Normal
NCT ID: NCT02649686 Org: User:
Start: 05/17/16 End: 11/12/19 Due: 11/12/20

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT02337530 Org: User:
Start: 05/26/15 End: 06/18/19 Due: 06/18/20

P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT01591421 Org: User:
Start: 09/06/12 End: 11/12/19 Due: 11/12/20

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase: N/A Priority: Normal
NCT ID: NCT03297606 Org: User:
Start: 03/23/18 End: 01/31/27 Due: 01/31/28

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05601440 Org: User:
Start: 06/13/23 End: 06/30/28 Due: 06/30/29

Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00754845 Org: User:
Start: 11/23/04 End: 04/19/17 Due: 04/19/18

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06205485 Org: User:
Start: 06/26/24 End: 06/30/30 Due: 06/30/31

STRIDE (durvalumab + Tremelimumab) with Lenvatinib Vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06880523 Org: User:
Start: 05/31/25 End: 12/31/28 Due: 12/31/29

Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04093167 Org: User:
Start: 05/26/20 End: 07/30/27 Due: 07/30/28

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Phase: N/A Priority: Normal
NCT ID: NCT03480776 Org: User:
Start: 07/24/18 End: 09/15/26 Due: 09/15/27

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03488693 Org: User:
Start: 10/16/18 End: 12/30/27 Due: 12/30/28

Economic Analysis of Alliance A041202 CLL Study

Phase: N/A Priority: Normal
NCT ID: NCT02414022 Org: User:
Start: 04/15/15 End: 04/09/26 Due: 04/09/27

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05998642 Org: User:
Start: 02/13/24 End: 12/31/28 Due: 12/31/29

Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT05470010 Org: User:
Start: 07/31/25 End: 12/31/26 Due: 12/31/27

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT03550391 Org: User:
Start: 11/22/18 End: 12/31/27 Due: 12/31/28

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Phase: N/A Priority: Normal
NCT ID: NCT06439225 Org: User:
Start: 12/30/24 End: 03/31/30 Due: 03/31/31

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06182774 Org: User:
Start: 04/10/24 End: 07/31/32 Due: 07/31/33

LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT06623461 Org: User:
Start: 04/07/25 End: 12/31/29 Due: 12/31/30

Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06391242 Org: User:
Start: 03/07/25 End: 01/01/28 Due: 01/01/29

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Phase: N/A Priority: Normal
NCT ID: NCT05640999 Org: User:
Start: 12/19/22 End: 06/30/29 Due: 06/30/30

STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision

Phase: N/A Priority: Normal
NCT ID: NCT06358469 Org: User:
Start: 12/10/24 End: 11/30/31 Due: 11/30/32

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Phase: N/A Priority: Normal
NCT ID: NCT03847649 Org: User:
Start: 03/09/20 End: 04/30/31 Due: 04/30/32

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT02619864 Org: User:
Start: 12/22/16 End: 02/25/20 Due: 02/25/21

Emotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04224974 Org: User:
Start: 01/06/22 End: 12/31/25 Due: 12/31/26

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02821013 Org: User:
Start: 10/31/16 End: 12/31/29 Due: 12/31/30